Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal [Yahoo! Finance]
Eliem Therapeutics, Inc (ELYM)
Company Research
Source: Yahoo! Finance
The combined company plans to focus on advancing TNT119, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. In June 2023, Eliem Therapeutics completed a review of its business, including the status of its programs, resources, and capabilities. The company has decided to halt further development of its Kv7 program and comprehensively explore strategic alternatives Also, Eliem entered a securities purchase agreement for a $120 million private placement. Eliem has agreed to sell 31.2 million shares at $3.84 per share. The private placement is expected to close concurrently with the closing of the acquisition anticipated in mid-2024. The combined company's total cash and cash equivalents are expected to be approximately $210 million. Eliem expects this will be sufficient to fund the combined company's planned operations into 2027 and to enable the potential attainm
Show less
Read more
Impact Snapshot
Event Time:
ELYM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELYM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELYM alerts
High impacting Eliem Therapeutics, Inc news events
Weekly update
A roundup of the hottest topics
ELYM
News
- SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the FirmPR Newswire
- LPCN, ADIL and CADL among pre-market losers [Seeking Alpha]Seeking Alpha
- CNN values your feedback [CNN]CNN
- ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to ShareholdersBusiness Wire
- Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement [Yahoo! Finance]Yahoo! Finance
ELYM
Earnings
- 5/11/23 - Miss
ELYM
Sec Filings
- 4/29/24 - Form 10-K/A
- 4/12/24 - Form SC
- 4/11/24 - Form DEFA14A
- ELYM's page on the SEC website